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Abstract: The eye presents extensive perspectives and challenges for drug delivery, mainly because
of the extraordinary capacity, intrinsic to this path, for drugs to permeate into the main circulatory
system and also for the restrictions of the ocular barriers. Depending on the target segment of the
eye, anterior or posterior, the specifications are different. The ocular route experienced in the last
decades a lot of progresses related with the development of new drugs, improved formulations,
specific-designed delivery and even new routes to administer a drug. Concomitantly, new categories
of materials were developed and adapted to encapsulate drugs. With such advances, a multiplicity of
parameters became possible to be optimized as the increase in bioavailability and decreased toxic
effects of medicines. Also, the formulations were capable to easily adhere to specific tissues, increase
the duration of the therapeutic effect and even target the delivery of the treatment. The ascending
of new delivery systems for ocular targeting is a current focus, mainly because of the capacity to
extend the normal time during which the drug exerts its therapeutic effect and, so, supplying the
patients with a product which gives them fewer side effects, fewer number of applications and even
more effective outcomes to their pathologies, surpassing the traditionally-used eye drops. Depending
on the systems, some are capable of increasing the duration of the drug action as gels, emulsions,
prodrugs, liposomes, and ocular inserts with hydrophilic properties, improving the absorption by the
cornea. In parallel, other devices use as a strategy the capacity to sustain the release of the carried
drugs by means of erodible and non-erodible matrices. This review discusses the different types of
advanced formulations used for ocular delivery of therapeutics presenting the most recent patents
according to the clinical applications.
Keywords: ocular drug delivery; patents; bioavailability; anterior eye segment; posterior eye segment;
targeted drug delivery
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1. Introduction
The ocular globe is an inimitable organic structure which comprises spectacular anatomic,
histological, and physiological features. Mainly, the ocular globe may be segmented in two chief
parts—the anterior and posterior portions. The anterior portion pertains about one-third of the eye and
is constituted by the aqueous humor, conjunctiva, cornea, iris, ciliary body and lens, with the remaining
second-third occupied with the posterior portion, made up of the choroid, neural retina, optic nerve,
retinal pigment epithelium, sclera, and vitreous humor [1–3]. According with the segment of the eye
elicited, several diseases can be pointed out. For the anterior segment of the eye a diversity of illnesses
can be named as conjunctivitis, anterior uveitis, or cataracts. The posterior portion of the eye is affected
by other pathologies such as age-related macular degeneration and diabetic retinopathy. Due to
this, therapeutics of the eye constitutes a challenge as it must comprise the formulation of specific
drugs with fine-tuned aspects to eliminate several problems related to barriers existent into the eye
structure, such as precorneal tissues, and the side effects commonly observed in the available products
in the market. Despite this, the most comfortable preparation for eye purposes are topical eyedrops,
specifically to treat diseases of the anterior portion of the eye. Another drawback in the formulation
aspect of drugs is related with the reduced time during which the formulation remains inside the
ocular globe, determining the success (or not) of a therapeutic. The past decades saw research in the
design and experimental analysis of new formulations aimed at increasing the residence time in the
ocular tract as well as developing safe and cost-effective systems capable of increasing the permeation
through different means [4,5]. To access the anterior segment of the eye, the commonly-used strategies
are now concerned much more with enhancers for viscosity and permeation applied to solutions and
to other formulations such as emulsions, ointments, and suspensions. In the last years, a significative
number of nanosized formulations were introduced in the market for healing purposes of the anterior
portion of the eye [6].
In another line, the posterior portion of the eye has been deeply studied to develop methods
capable of safely delivering specific drugs to treat conditions related with chronic vitreoretinal illnesses.
With these advances, further improvements are aimed to improve the capacity to penetrate the ocular
barriers and to eliminate majority of the side effects verified with usual formulations [7,8]. Other factors
are also essential, such as the ease of formulation, the reduction or even elimination of irritation
in the ocular tissues, increasing the time of permanence in the precorneal tissues with improved
bioavailability, and the capacity to sustain the delivery of the drugs. The current progressions in the
research field of ocular systems do require the assiduity of scientists specialized in the formulation
of drugs to establish a rationale through the assay of designing a system until the synthesis of this
and consequent improvements in its features. The available review articles all point to the gradually
increased presence of nanoparticulated systems for these purposes with other strategies also attained
as the combination of traditional systems with novel techniques to improve their efficacy [7].
To surpass the boundaries imposed by the ocular globe to the delivery drug systems and,
concomitantly, to enhance the bioavailability of the administered formulations, several novel systems
were specifically designed to circumvent such problems. It is the case of aqueous gels, dendrimers,
emulsions, implants, liposomes, nanomicelles, nanoparticles, ointments, suspensions, and many others
forward described. The current review aims to make available a vast array of the patented available
systems for therapeutics of ophthalmic illnesses [9].
2. Drug Delivery Systems for Ocular Route
Drop instillation performed by a topical path to deliver a given drug into the lower precorneal
segment of the eye is a broadly known method to make an administration with the compliance of the
patient. Nevertheless, from the original applied dose, only about 20% is kept in the precorneal segment
of the eye as a consequence of the reflux phenomena happening during eye blinking. The diffusion of the
drug across the corneal tissues is largely driven by the concentration of drug accessible in the precorneal
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sites. Yet, to achieve an effective ocular distribution of the drug using eye-drops it is mandatory to
achieve a higher retention time in the corneal tissue and elevated corneal permeation [3,10].
Ocular drug transporters may alter drug’s efficacy and therefore, an evaluation of the interactions
of new drug molecules and drug delivery systems with selected transporters is required during drug
development [11]. These ocular transporters can be divided into two major families: the solute carrier
(SLC) family and the ATP-binding cassette (ABC) family. SLC transporters use facilitated diffusion
or couple an ion or electrochemical gradient to transfer their substrates across the cell membrane.
ABC transporters use adenosine triphosphate (ATP) as the energy source [11].
Aiming the last feature some techniques as prodrugs, iontophoresis, cyclodextrins or agents
capable to form ion-pair are considered. Nowadays the pharmaceutical markets present a wide offer on
ophthalmic products and, in 70% of the cases, the prescribed medicines are mainly eye drops. This fact
is supported by the easiness of application of this formulation, the compliance and suitability by the
patients, the stability of the formulation and the relation cost-effectiveness [12–14]. However, there are
a wide variety of different ophthalmic formulations (Table 1).
Table 1. Types of ocular drug delivery systems.
Topical dosage forms
Conjunctival Inserts
Contact Lenses
Gels
Nanoparticles
Mucoadhesive Polymers
Ointments
Solutions
Suspensions
Intraocular dosage forms
Implants
Nanoparticles
Inserts
2.1. Conventional Topical Formulations
2.1.1. Eye Drops
The formulations of eye drops possess a variety of factors that turn them into a widely-prescribed
form (Table 2). They are safe, take immediate action after applied, have high patient-compliance,
are suitable for the product, and, above all, are non-invasive.
The application of eye drops is characterized by a permeation of the supported drug by a pulsatile
mechanism which occurs subsequently to the topical instillation of the drops, with further quick
declination of the drug concentration following a kinetic profile corresponding roughly to a first
order elimination process. In consequence, to expand the time of contact of the drug, the capacity of
permeation and the critical bioavailability of the desired molecule(s), several modifiers are powerful
enough to be operated in eye drop formulations, such as cyclodextrins, enhancers of viscosity and of
permeability [3,5,15,16].
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Table 2. Therapeutic molecules, biological targets and potential clinical applications.
Patented System Clinical Applications Year References
Derivatives of Omega chain,
hydroxyeicosatetraenoic acid, and
15-hydroxyeicosatetraenoic acid
Dry eye 2001, 2003 [17,18]
Isolated de novo polypeptides
Combination of inhibition of
proliferation of HUVEC cells with
anti-VEGF activity
2004 [19]
Analogue peptides to bind the
sequences Pro-Gly-Pro chemotactic
factors of polymorphonuclear
leukocytes
Several ocular illnesses and ocular
injuries induced by alkali
compounds
2004 [20]
Piperidinyl prostaglandin E
derivatives Glaucoma 2005 [21]
Agonist of EP-4 Glaucoma 2004 [22]
Flurbiprofen and ketorolac
amide-derivatives for topical
administration
Inflammation and angiogenesis of
the ocular mucosa 2002 [23]
Solution of concentrated trypsin Cataracts in the eye 1978 [24]
Toxin extracted from Clostridium spp. Uveitis or inflammation of theocular mucosa 2004 [25]
Lipopolysaccharides aimed to
augment the levels of polypeptide
beta defensine-2 (hBD-2)
Infections and wounds in cornea 2006 [26]
Calcium blockers Proliferative Vitreoretinopathy 2003 [27]
Analogues of prostaglandins Glaucoma 2008 [28]
Derivatives of dithiolane to inhibit
peroxisome proliferator-activated
receptor-alpha and gamma
Illnesses of posterior eye portion 2000 [29]
Derivatives of indazole to inhibit
tyrosine kinase Illnesses of posterior eye portion 2006 [30]
With an enhancer of viscosity, it is possible to reach some variation in important variables such
as the bioavailability and the time of permanence in the precorneal tissues. The most widely-used
viscosity enhancers are hydroxyethyl cellulose, hydroxymethyl cellulose, sodium carboxymethyl
cellulose, and a combination of hydroxypropyl methyl cellulose and a polyalcohol. The employment
of these substances aims to augment the uptake by corneal tissues through a mechanism of slight
disruption of the integrity of the mentioned tissue. Many other compounds are reported to possess
similar properties in this context such as preservatives, chelating compounds, bile salts and surfactant
molecules, being applied as permeation enhancers. The appliance of these enhancers in the context
of ocular solution aims to considerably increase the bioavailability of the compounds; in the studies
already performed just a few demonstrated the presence of toxicity associated with these substances.
Still, the researchers are continuously evaluating the potential of toxicity of every new developed
compound with the finality to assess its potential to be applied in the formulation of new products to
improve the ocular therapeutics [31–35].
Researches carried out by Hornof et al. exposed the fact in which a compound used as an
excipient, polycarbophil-cysteine, did not affect the tissue structure of the eye and was considered safe
enough to be applied in the production of formulations for ocular route delivery [36]. The remarkable
cyclodextrins are also considered agents capable of encapsulating hydrophobic compounds, in this
case drugs, and promoting dissolution in hydrophilic substances as an aqueous solvent. The present
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detail is decisive for better delivering drugs into the surface of membranes of biological systems.
Nevertheless, it must be considered that a cell membrane is constituted of lipophilic compounds,
phospholipids, and cholesterol, mainly, which are not compatible for dissolution purposes with
hydrophilic substances. On behalf of such, cyclodextrins do not pass through the membrane of the
cell, but the encapsulated drug may do so by releasing from the inner core of the formulation and
penetrating the biological barrier. For ocular targeting the best bioavailability of a given compound
was achieved using cyclodextrins in concentrations lower to 15% [14,37,38].
Among the techniques used to get closer to an optimal bioavailability, excipients with diversified
functions as cyclodextrins or enhancers of viscosity could be found. The relatively lipophilic membrane
of the corneal tissue has low affinity for the hydrophilic cyclodextrin molecules and therefore they
remain in the exterior aqueous membrane being cleared by the lacrimal fluid.
Regarding the molecules’ ability to act as penetration enhancers, their choice must be carried
out according to their potential to sensitize the eye globe. According to these facts, the development
of other compounds with improved properties and without harmful effects, regarding the targeted
eye structures, has been explored in the last decades. As so, emulsions, ointments, and suspensions
were explored attempting to achieve better features such as bioavailability of the encapsulated drugs,
increased time of residence in the precorneal tissues, and higher solubility values [39–41]. Despite the
current state-of-the-art and industry methodologies with regard to the manufacture of novel products
based on nanotechnological approaches, the traditional formulations are still significantly marketed.
Yet, the prior formulations have serious side effects associated to their employment, such as ocular
tissues irritation, inflammation, inequal stability, and blurred vision. The recent research focusses
mainly in improving the described critical features and reducing the side effects imputable to these
formulations in order to produce better performances in an in vivo organic environment, avoiding
serious undesirable effects. A lot of efforts are being made to try to carry the desired drugs to the
posterior tissues of the eye using common formulations. In the next sections are described, for each
formulation, the particular advances attained until the present and the overall perspectives for the
next few years in what does respect to formulation advances.
2.1.2. Emulsions
The formulations with an emulsion nature are keen to increase the bioavailability of the
encapsulated drugs as well as the solubility. The principal formulative mechanism to yield this
design is based on two types of emulsions—oil-in-water (O/W) and water-in-oil (W/O). To be applied
in the delivery of drugs to ocular tissues the favorite type is the O/W rather than W/O, mainly due to
the favorable characteristics as diminished irritation induced in the target tissues as well as improved
tolerance of the eye to O/W emulsions [5,42,43]. Some current examples of available medicines based
on the technology of emulsion are the AzaSite®, Refresh Endura® and RestasisTM [44–46]. A vast
array of scientific studies was able to validate the advantages related with the use of emulsions as the
increased time of residence in precorneal tissues, the increased permeation of drugs in the corneal
tissues, the capacity to keep the release of the drug and, so, rising the bioavailability of the drug [47,48].
Recently, a study conducted by Tajika et al. proved the increased anti-inflammatory capacity of a
derivative of prednisolone, [3H]-difluprednate, at a concentration of 0.05%, formulated as an emulsion.
The results carried out in the rabbit eye model proved that the designed emulsion was successful
in delivering the therapeutic content only to anterior eye tissues with a very small amount of drug
contacting with the posterior portions of the eye after single or multiple instillations. Once the single
and several instillations of topical drops were applied, the tests to reveal the location of formulation
through detection of radioactivity revealed, by decreasing order of intensity, the sites where the
formulation was spotted: cornea, ciliary body of the iris, retina-choroid, conjunctiva, sclera, aqueous
humor, lens, and vitreous humor. Overall, the quantity that entered the systemic circulation was
insignificant. Subsequently to a period of 168 h, about 99.5% of the radioactivity was detected in both
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feces and urine. Based in the anterior evidences it can be firmly proposed that difluprednate emulsion
may be considered as a probable product for the therapeutic of inflammatory ocular conditions [49].
Several emulsions fabricated using additives of lipidic sources as soybean lecithin or stearylamine
were scrutinized to be carriers for drugs as azithromycin aiming to increase the parameters of
bioavailability and retention in the corneal tissues. To assess the variation of the features of
elimination pharmacokinetics for tears, three distinct doses of azithromycin—3.0 mg/mL, 5.0 mg/mL,
and 10 mg/mL—in two different formulations types—emulsion and solution—were used. To accomplish
so, the animal model of rabbits was used to perform the studies in vitro after a drop administration
by topical route. In relation to the emulsion, it was perceived that the formulation was suitable as
a delivery instrument and even braked the release of drug and, due to this, enhanced the chemical
stability of azithromycin at two points—pH of 5.0 and 7.0—compared to usual aqueous solutions, and
increased the time of permanence in the precorneal tissues. Combining the results, it is possible to
perceive that emulsions with a strong lipidic character may be robust candidates for future products
aiming the ocular delivery of drugs [50].
Another premise was stated and tried—the derivatization of active pharmaceutical ingredients
with concomitant combination of the drug and an emulsion to improve the bioavailability in the ocular
tract. This methodology offers the possibility of reducing irritation in the eye globe and enhancing the
effect of the drug. To assess such idea the research team of Shen and collaborators tried to enhance
the bioavailability character of a derivate of a commonly used drug—flurbiprofen acetyl—employing
to achieve this finality a lipidic excipient, castor oil, and a stabilizer, Tween 80, to properly manage
the formulation. The experimental design included four distinct formulations, varying both the
concentrations of castor oil and Tween 80, between 0.1% to 2.5% and 0.08% to 4.0%, respectively.
They found one of their four formulations suitable to massively increase the drug concentrations in the
aqueous humor and the parallel studies of biocompatibility showed reduced capacity to induce ocular
irritation [51].
Other studies carried out by other teams of researchers revealed that supplementary polymers to
coat the emulsion formulations may also be appropriate as it is chitosan or an ether of hydroxypropyl
methyl cellulose (HPMC). The posterior outcomes proved the efficacy of chitosan as coating in the
improvement of the permanence time in the precorneal tissues with a consequent increase in the ocular
bioavailability [52]. Another study established a comparison between an emulsion made of castor oil
and polysorbate-80 plus a content of indomethacin, and a parallel formulation made with the same
substances but with and additional coating with chitosan. The animal model used was the male albino
rabbit and the method used to apply the formulation was the drop instillation by topical route. Results
proved an increased time of residence in the tear fluid of the coated formulation in relation to the
non-coated by a factor of 1.5-fold. Also, to complement the studies, the concentrations of the drug
were assessed in the corneal tissues, conjunctiva and aqueous humor being 5.3 and 8.2-fold higher in
cornea than in conjunctiva or aqueous humor, respectively [53]. Moreover, Muchtar and colleagues
developed a submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol, due to the low
drug solubility, in order to decrease the effect on intraocular pressure in rabbits [54].
2.1.3. Ointments
Also included in the category of topical formulations ointments are used too as carrier systems
for drug delivery. The usual melting points of these systems are near to the ocular temperature of
34 ◦C due to their constitution base on a combination of solid and semisolid hydrocarbon molecules.
But what hydrocarbon should we choose for a determined purpose? This simple detail produces much
difference in the biocompatibility of a formulation as the substance must not be rejected by the body in
order to prevent further organic side reactions and even to warrant the effectiveness of the purposes of
the formulation to increase the bioavailability of the drug and to sustain the process of delivery [55–58].
The antibiotic vancomycin has in its backbone a structure of glycopeptides with proved outstanding
activity against the effects of the aerobic and anaerobic microorganisms which stain positive by the
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Gram technique and the Staphylococcus aureus, resilient to the therapeutics with methicillin and
cephem [59]. Despite this extraordinary therapeutic effect, few or even none of the topical formulations
were available to be commercialized [60]. Improved outcomes related to the permeability of healthy
ocular tissues to vancomycin were not projected. Despite this, slight positive results were observed in
clinical trials for ocular pathologies, with this drug. But why such achievements? One of the reasons
pointed out is related with the possibility of breaks in the barrier of the ocular globe leading to less
selectivity in the uptake of foreign compounds with consequent elevated permeation [61].
Fukuda and collaborators wanted to study the dynamics of vancomycin hydrochloride formulated
as ointments for ophthalmic purposes in the interior environment of the eye of rabbits linking this
phenomenon with the extraocular infection with MRSA. To determine the minimum concentration
which inhibits the development of the MRSA in bacterial infections, the investigators used a control
group of rabbits, and as experimental condition a group infected with Bacillus subtilis, this last group
generated using an intracorneal injection of a solution of Bacillus subtilis into the central part of the
parenchyma. The value for the prior parameter ranged the 1.56 µg/g. After application of the ocular
ointment formulation to both groups, with a concentration of 1.0%, it was verified that in the infected
group the concentration was 3.68 µg/g ± 1.38 µg/g within 240 min after administration while in the
normal group the values were of 0.49 µg/g ± 0.97 µg/g only after 120 min showing that Bacillus subtilis
infected animals would benefit from a better therapeutic performance of the antibiotic molecules [62].
In an additional study, carried out by Eguchi et al., an array of four distinct ointment formulations
was prepared through variation of the vancomycin concentrations—0.03%, 0.1%, 0.3%, and 1.0%—in
a mixture of paraffin and Vaseline in a proportion of 1:4. To further assess the efficacy of the
designed formulations the rabbit model with induced MRSA keratitis was used and the parameter
evaluated after topical application of the formulation. The results demonstrated that the concentrations
below 0.3% were not successful in avoiding the formation of subsequent lesions to the infection as
abscesses. Nevertheless, the prior mentioned concentration was believed to be ideal for formulation as
a therapeutic option for corneal keratitis derived from the MRSA infection as the results were keen
enough to validate a period of 14 days without relapse of the infection [63].
Even though actual researchers push harder the limits of knowledge in this field to attain better
efficacy on the developed materials, there is a parallel existence of other problems related with everyday
formulations in use as emulsions, ointments, and suspensions, largely recognized by their side effects
induced in the eye as blurred vision, redness, or itching. Another topic with possible implications is
related with the continuous/chronic administration of the prescribed drugs, risk factor to achieve future
systemic worries. To circumvent these actions and to improve the overall quantity of a given drug
administered to the eye the exploratory strategies use modern approaches based on nanotechnological
achievements because of the optimized properties of these last systems [64–66]. The following sections
will present and discuss briefly the contribution of several formulation systems to the advances
observed in the last decades in the field of pharmaceutics.
2.1.4. Suspensions
These pharmaceutical forms are chemically defined as being dispersions of drugs, using for
such purpose a hydrophilic solvent possessing an agent of dispersion or a suspension obtaining a
final solution with a saturated character. Furthermore, this type of formulation will be suitable once
it does not require an invasive application method. The particles which constitute the suspension
are taken by the precorneal tissue, enhancing the contact time of the drug with the tissues, and also
increasing the period during which the drug is therapeutically active. One of the particularities of
these systems is the required well-designed size of the particles constituting the formulation, because
this parameter affects directly the duration of the drug effect [67,68]. Using the TobraDex® formulation
it was verified in the rabbit animal model that the drugs dexamethasone and tobramycin exhibited
elevated concentration values. Overall, the higher the size of the particle, the longer the retention time
will be in the organism, and the slower the dissolution of the drug. On behalf of this it is anticipated
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that particles with an suitable size produce an excellent activity of the drug [69]. A couple of medicines
are available worldwide to be employed in the treatment of infectious diseases. TobraDex® is a
suspension composed by a combination of an antibiotic (tobramycin at a 0.3% concentration) plus a
steroid drug, dexamethasone (at a 0.1% concentration), aimed to treat patients with a positive feedback
to the steroid therapeutics. This product had high viscosity, which was its foremost disadvantage
the [70,71]. Fresh efforts leaded by Scoper et al. tried to diminish the values of the referred parameter
for the prior product and to enhance its capacity to efficiently eliminate microorganisms. The aims
of this project were to develop a novel suspension with improved features related with quality,
kinetics, and permeation through tissues. Merging efforts lead to the development of TobraDex ST®,
a new formulated suspension consisting in tobramycin at a concentration of 0.3% and dexamethasone,
a steroidal molecule, at a concentration of 0.05%. The results demonstrated a reduced settling for
TobraDex ST® suspension in comparison to control, TobraDex®, with values of 3.0% for the first, over a
period of 24 h. Also, the innovative formulation had higher effectiveness in the therapeutic effects against
the action of Pseudomonas aeruginosa and Staphylococcus aureus and, in clinical trials with humans, the
new formulation achieved augmented dexamethasone concentrations in the aqueous humor comparing
to the TobraDex® [69,72]. With this background is possible to conclude that the novel developed
formulation, TobraDex ST®, has the potential to substitute the TobraDex® marketed formulation due
to four mainly characteristics—augmented bactericidal effect, improved pharmacokinetics, upgraded
intrinsic features of the formulation, and enhanced compliance of the patients.
Another project to evaluate the performance of the drug rebamipine, as a suspension to treat
the condition of dryness of the eye, was carried out through a multicenter clinical trial of phase II,
double masked and randomized, conducted for a period of 4 weeks. The conditions applied were a
placebo as control and two different concentrations for rebamipide, 1.0% and 2.0%. The most important
parameters—efficacy and safety of the formulation—were determined using humans after a topical
instillation procedure. Obtained results incorporated several different characteristics. Using the
staining methods of Lissamine green for conjunctive membrane and fluorescein for cornea tissues
at determined periods of 2 and 4 weeks it could be inferred that the outcome were dose-dependent
in the three tested conditions: Placebo, 1.0%, and 2.0% concentrations. Respective to the production
of tears it was observed no significative statistical alteration, in comparison to the control, between
the first day to the fourth week. Despite such, the produced film of tears was significantly altered
in the assays using the concentrations of 1.0% and 2.0% of rebamipide, namely in the break-up time
parameter when compared to the placebo. Also, comparatively to placebo, the patients reported
enhancements in their conditions. The occurrence of adverse effects was also analyzed with dysgeusia,
nasopharyngitis, and irritation of the eye globe increasingly reporting from the placebo, passing
through the 1.0% to 2.0% concentrations of the drug. In spite of these occurrences the side effects
disappeared after retrieval of treatment and the studies proved that the formulated suspensions are
tolerated and present effectiveness in the treatment of dry eyes conditions. Weighting the outcomes of
the two different concentrations allowed the realization that the 2.0% concentration was more effective
than 1.0% formulation [73].
2.2. Nanotechnological Inspired Delivery Systems
The last decades of scientific progress were extremely fructiferous regarding therapeutic
developments for ocular diseases treatments. The uprising of nanotechnology in combination
with already well-established pharmacological compounds lead to the currently used tactics in the
treatment of both anterior and posterior portions of the eye (Table 3).
With the proper fine-tuning, the nanoparticulated systems may assure reduced side effects with
augmented bioavailability and better capacity of absorption. Several examples are used in nowadays
practice being nanocarriers: Dendrimers, liposomes, nanoparticles, nanosuspensions, and nanomicelles
are just a few cases of the available arsenal for ocular treatment of pathological issues with many of
these materials demonstrating auspicious outcomes (Figure 1) [74,75].
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Table 3. Drug delivery systems for ocular applications.
Patented System Clinical Applications Year Reference
Topical delivery systems containing neurotransmitters and neuropeptides Dry eye 2008 [76]
Topical delivery system containing modulators of the adhesion molecule for
neural cells—polysialic acid—as INF, EGF, and NGF Dry eye 2008 [77]
Several formulations as in situ gels, solutions and suspensions for delivery
of BOL-303213-X Anti-angiogenic and anti-inflammatory effects in the eye 2008 [78]
Hydrophilic gel for delivery of lidocaine hydrochloride Local anesthesia of the eye 2008 [79]
Intravitreal injection of anti-VEGF molecule using both lyophilized and
unchanging liquid forms
Handling of illnesses related with the posterior segment of
the eye 2007 [80]
System to deliver a drug to cornea and sclera stromal cells with a
hollow microneedle
Handling of illnesses related with the anterior and posterior
segments of the eye 2007 [81]
Encapsulated small and macromolecules for suprachoroidal delivery Handling of illnesses related with the posterior segment ofthe eye 2007 [82]
Metal chelator, EDTA, and transport enhancer, methylsulfonylmethane,
as eye drop formulation Diabetic conditions 2010 [83]
Rapamycin as self-emulsion Handling of illnesses related with the posterior segment ofthe eye 2006 [84]
Microparticles-engineered formulation containing rapamycin Wet Age-related Macular Degeneration 2005 [85]
Tacrolimus delivered as formulated eye drops or ocular ointment Immune-related illnesses of the anterior section of the eye 2003 [86]
Oral formulation containing essential fatty acids omega-3 and omega-6 Dry eye 2006 [87]
A formulation containing amino acids, minerals, phytonutrients and
vitamins to nurture the eye
Handling of illnesses related with the anterior and posterior
segments of the eye 2003 [88]
A formulation for topical application containing ketotifen fumarate Antiallergenic 2005 [89]
A jelly formulation with pilocarpine hydrochloride was engineered through
combination of Carbopol and Pluronic Glaucoma 2003 [90]
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2.2.1. Nano-Enhanced Contact Lens
Contact lenses cover the cornea using their curved shape and thin surface. Once applied they
adhere to the wet surface in the exterior of the eye mainly due to surface tension phenomena. A vast
range of drugs have been formulated to be delivered through the ocular route such as antihistamines,
antimicrobials, and β-blockers. The existence of the contact lens allows the drug molecules to stay for
longer periods in contact with the ocular tissue with increased flux crossing the cornea and less of
the drug lost to the lacrimal duct [91,92]. The common method to load the contact lens with a drug
supply is to immerse them in a solution of a given drug. In performed studies the immersed contact
lens demonstrated a better profile of release of drug in comparison to usual eye drops systems [93].
A study completed with dexamethasone demonstrated that this drug had higher bioavailability when
formulated in a contact lens made up of poly(hydroxyethyl methacrylate) in contrast with eye drops [94].
Despite these advantages, the loaded lens has some drawbacks such as insufficient and irregular drug
loading with further shorter time for release of the contents [71]. To outdo these limitations, two types
of formulations were developed consisting of a contact lens loaded with drug-loaded nanoparticles and
a contact lens printed on a molecular level. The first technique makes use of the known nanosystems
such as liposomes or micelles to capture the drug and then disperse the systems in the material which
constitutes the contact lens. Another study conceived contact lens loaded with nanoparticles to deliver
lidocaine. These contact lenses were arranged through dispersion of drops of microemulsion containing
lidocaine or liposomes in hydrogels made up with poly-2-hydroxyethyl methacrylate (p-HEMA).
The results showed that lidocaine was released through a period of, approximately, 8 days, and contact
lenses loaded with nanoparticulated systems were very auspicious for extended ocular delivery [95].
The contextual application of systems with stimuli-responsive features is a comprehensive tool
to circumvent the previous referred problems [95,96]. Using variables such as temperature or pH
the engineered particles may undergo reactions leading to the release of their content only in the
ocular milieu, avoiding the prior issues. Regarding the manufacture and performance of contact lenses
these were able to show good profiles of both encapsulation and release with regard to their drug
content [95]. An experimental study using contact lenses compared the method of production with the
lenses derived from molecular printing revealing a 1.6-times higher capacity to encapsulate the drug
timolol in comparison to contact lenses fabricated using usual approaches. Also, the first lenses were
able to endure the release of timolol [97]. An extra study using printed lenses containing the drug
ketotifen fumarate (directly stamped) revealed a higher bioavailability of the drug in comparison to
the usual process of soaking lenses or even to commonly-used eye drops. The relation between the
parameter of bioavailability between the drug-stamped lenses and the non-printed lenses was 3-fold
higher for the first referred [98]. Such results clearly demonstrate the capacity of the drug-stamped
lenses to be much more effective in the delivery of drug to the desired tissue in relation to the other
two referred formulations.
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2.2.2. Dendrimers
Dendrimers possess a star shape with a nanosized, multiple branched polymeric web. Dendrimers
are accessible with several modifications regarding the terminals of the chains with multiple functional
groups being present as amine, carboxyl, or hydroxyl groups. They also have a range and diversity of
molecular weights. With the capacity of wear on dynamic chemical groups also comes the possibility
of conjugation with other molecules selective according to the desired milieu. These systems require
an optimization of their chief characteristics as functional groups, molecular geometry, charge of
surface, and molecular weight, to obtain a system affordable to apply in the context of drug carrying.
On behalf of the extraordinary structure of dendrimers, lipophilic or hydrophilic drugs may be
encapsulated [99–101].
Regarding the ocular route purpose, the dendrimers using poly(amidoamine) (PAMAM) as
structural basis are widely applied. In a study carried out by Vandamme and collaborators they
stressed the possibilities in the application, as carriers, for ophthalmic miotic and mydriatic effects of
the drugs, respectively, pilocarpine nitrate and tropicamide designed as PAMAM dendrimers [102].
To reach acceptable results the researchers used the variable residence time in the rabbit eye for
fluorescein in saline formulation and fluorescein in PAMAM formulation. The bioadhesive control
formulation applied was a 0.2% (w/v) Carbopol solution. The results demonstrated that both PAMAM
and Carbopol solutions had considerably higher values for the residence time in relation to saline
formulation. Because of this, the employment of dendrimers shall be an available opportunity to
expand the previous referred variable in this study with further better therapeutic outcomes because
of the increased bioavailability of the drugs. In parallel, the results also demonstrated that PAMAM
formulation was keen to reveal increased miotic and mydriatic effects in albino rabbits.
Also, to prevent the formation of wound tissues because of surgery for filtration of glaucoma,
immunomodulation, and blockade of angiogenesis were attained, respectively, through the application
of novel synthesized compounds derived of dendrimers from PAMAM containing glucosamine
(GA) and glucosamine 6-sulphate (GAS) with consequent diminution on the formation of scar tissue.
The development of this study demonstrated a positive influence on the evading of formation of scar
tissue after the referred surgery with the administration of GA and GAS [102,103].
2.2.3. Intraocular Implants
These materials are pharmaceutically engineered to deliver the drug cocktail content in a
determined location during a specified time range preventing the prior requirement of several
injections in the ocular tissues with further developing inflammatory processes and infections. If aimed
to deliver the drug into the posterior portions of the ocular globe these implants are physically settled
in the proper place through a surgical procedure that requires a small incision in the region of the
pars plana, being anteriorly located to the retina but posteriorly to the lens [104,105]. Despite the
invasiveness of the method, it has achieved an increasing interest as a result of the positive returns
when regarding to the capacity to relay during much longer times, releasing the same amount of
drug to the tissues, evading the blood–retina barrier and diminishing the side effects related with the
presence of the drug [106,107]. A variety of devices were designed and manufactured to be applied
as ocular implants for therapeutic of illnesses with a chronic vitreoretinal nature. These devices are
also obtainable in two different chemical structures—the biodegradable and the non-biodegradable
ones. The latter are configured with zero-order kinetics, which means they can release for longer times.
They use a chemistry based on various polymers to become available as ethylene vinyl acetate (EVA),
polyvinyl alcohol (PVA), or even polysulfone capillary fiber (PCF) [108,109]. As actual examples of
products already developed for this aim are Retisert® and Vitrasert®. The first was approved by
the Food and Drug Administration (FDA) as a pharmacological tool for the pathology of chronic
uveitis on the posterior portion of the ocular globe. It consists on several foil of silicone with PVA.
It allows a controlled release of fluocinolone acetonide for a period up to 3 years, which also proves
that the implant is successful in controlling the inflammation with consequent better visual acuity and
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diminished reappearances of uveitis. Nevertheless, some side effects are present, like the possible
development of cataracts and high intraocular pressure [110–112].
The second is an implant for intraocular delivery of ganciclovir using a controlled-release
mechanism, also approved by the FDA, to treat cytomegalovirus retinitis caused by acquired immune
deficiency syndrome (AIDS). The device possesses weighs 4.5 mg and has a shell made of PVA/EVA
which allows the unhurried release of the therapeutic principle for a period ranging from 5 to 8 months.
In parallel with this reality the product does not present systemic toxicity and is available at a reduced
price [113–116].
The prior examples of devices reveal the potential of nanosystems in future therapeutics, but the
non-biodegradable materials have the drawback of requiring a double surgery procedure—to implant
and to remove the drug-releasing system—leading to a much more extensive treatment, possibly
more painful for the patient and with less compliance. Additionally, other possible physiological
occurrences may border the application of these inventions, such as cataracts, retinal detachment,
or hemorrhage [117,118].
The intraocular implants are also available in the category of biodegradable products, which are
receiving a considerable amount of attention by the medical public due to their biocompatibility
and capacity to sustain the delivery of drugs. Biodegradable implants, including nanoparticles,
are manufactured using polymers such as polylactic acid (PLA), PLGA, polycaprolactones,
or polyglycolic acid (PGA), producing an instrument that does not require removal after implantation,
a significant advantage in relation to others implants of non-biodegradable origin [118,119].
Some practical examples of medical devices used to this purpose are the biodegradable products for
ocular deliver Surodex™ and Ozurdex®. The first is intended to treat macular edema whilst the second
is purposed for the treatment of intraocular inflammation, both using dexamethasone as a therapeutic
agent. Surodex™ was engineered with a lattice composed by hydroxypropyl methyl cellulose (HPMC)
and PLGA which act as a polymeric core. It is further implanted in the anterior chamber of the eye
to control the processes of inflammation after surgeries in patients with cataracts. The product can
sustain the release of dexamethasone for a period between 7 to 10 days being the anti-inflammatory
provided effect superior in relation to other topical corticosteroids [70,120,121].
Ozurdex® was approved by June 2009 aiming to treat macular edema. It is an implant settled by
intravitreal procedure with good features such as biocompatibility and biodegradability. This product
also has a singular characteristic—it uses the technology NOVADUR® to achieve a suitable delivery
of dexamethasone. This technology uses the capacity of PLGA polymeric lattice to encapsulate the
drug, and to slowly degrade and form monomers of glycolic acid and lactic acid, which allows for
an extended release period up to 6 months. The submission of Ozurdex® to accurate clinical trials
emphasized the capacity of this product to reduce the overall loss of vision (potency) and upgrade
outcomes with respect to vision perception in eyes possessing macular edema in association with
branch or central retina vein obstruction. Ozurdex® is also pointed, as a consequence of several clinical
studies, to treat diabetic retinopathy and Irvine–Gass syndrome [122–124].
2.2.4. In Situ Gelling Nanosystems
The designation used refers to the solution with a polymeric nature that may experience a
transition of phases between solution and gel forming then a gel presenting viscoelastic features
as a result of a stimuli from the surroundings. The process of gelation is also prompted by other
modifications such as pH variations, temperature, presence or absence of ions, and incidence by
ultraviolet (UV) radiation. To develop and apply a system such as this in the ocular structure the
chief factor chosen was the temperature to further develop thermosensitive gels [125,126]. A vast
array of polymers, sensible to variations in temperature and acceptable to be applied in the eyes,
is described in the available literature. Among these compounds are molecules such as polyethylene
glycol, poly(lactide), and poly(glycolide) and their derivatives, polycaprolactone or even chitosan (the
latter being a highly positive polymer). These chemicals use a mechanism based on the formation of
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micellar aggregates when the temperature reaches a certain threshold, jellifying due to phenomena of
packing or aggregation. Intended to be used as drug delivery vehicles these systems can be modeled
to jellify after mixed with the desired drugs, both as solutions, which will further form a gel in the
milieu of administration at a temperature between the physiological values [125,127–129]. Related
to the anterior and posterior sections of the eye, these thermosensitive formulations revealed good
results by increasing the bioavailability of the drugs [130,131]. As well, Gao and collaborators made
a screening on the capacity of a gel with thermosensitive properties, constituted by a polymeric
network with a frame A-B-A, PLGA-PEG-PLGA, to efficiently carry dexamethasone acetate into
the ocular globe. The formulation was projected for a concentration of 0.1% (w/v) in 20% of the
polymeric mixture previously described and then injected into a rabbit’s eye. In comparison to
an eye drop formulation the concentration of therapeutic agent in the anterior segment of the eye
was significantly higher in the polymeric formulation possessing also the highest area under curve
(AUC) values. The ratio of increase in the polymeric formulation comparatively to the eye drop
formulation was about 7.0 and 7.98 for the maximum concentration and AUC, respectively [132].
The outcomes from this study reveal the potential of a polymeric formulation to be used in the
context of ocular delivery due to the increased bioavailability. Rieke et al. described the capacity to
sustain the delivery of ovalbumin to the choroid and retina portion of the eye of a rat subsequently
to the administration in the subconjunctival layer of the eye as a product—ReGel™—which, by turn,
consists in a biodegradable and thermosensitive polymeric network of PLGA-PEG-PLGA with the
previously-described molecule. The team assessed a period of 14 days during which they stated that in
the choroid, retina, and sclera of the rats the concentration of ovalbumin was kept at detectable levels.
A combination of poly(N–isopropylacrylamide) and poly(ethylene glycol) diacrylate as hydrogels
was tested to attain a sustained release of macromolecules like immunoglobulin G (IgG) or bovine
serum albumin (BSA). The results demonstrate that BSA was able to be prolongedly released for
in vitro for almost 3 weeks [133]. In a recent patent, the inventors have designed polyethyleneglycol
(PEG)-polyacetal (PA) copolymer and polyethyleneglycol (PEG)-polyacetal (PA)-polyorthoester (POE)
copolymer for the drug delivery purposes. This solution form will convert to gel form at body
temperature [134].
The studies previously described show a great capacity of these thermosensitive gels to reduce
side effects of the employed therapeutic molecules, diminish the required posology, increase the
bioavailability of drugs with parallel use of sustained release systems, and even extended contact
time of the drugs with the cornea tissue. Overall, these thermosensitive systems constitute a suitable
strategy to be employed for the delivery of drugs for ocular diseases [132].
2.3. Liposomes
These systems are composed by vesicles of lipid nature arranged on a single or multiple
phospholipid bilayer design with a hydrophilic core. Liposomal systems are classified based on their
size and on their bilayers of phospholipids. As so, they can be categorized as small unilamellar,
with sizes between 10 nm and 100 nm, large unilamellar, with a range of sizes between 100 nm and
300 nm, and multilamellar if they have more than one bilayer and, so, are bigger than 300 nm [134,135].
Regarding the ocular application route, liposomes are here described as suitable systems to deliver
drug content because of their high efficiency to encapsulate both hydrophilic and lipophilic drugs,
high biocompatibility, and a structure similar to the natural cell membrane. Liposome formulations
were accurate enough to efficiently delivery their contents in the anterior and posterior portions of the
eye, according to numerous scientific studies [136,137]. A fresh study, developed by Natarajan and
collaborators, on the delivery of latanoprost encapsulated within liposomes and applied in the anterior
portion of the ocular globe demonstrated a capacity to reduce the intraocular pressure in the eye of
a rabbit, for a time range of 50 days [138]. Related with the anterior segment of the eye, the actual
frontline in research of the topic is pulling the limit on the residence time of drugs with precorneal
tissues through the integration of lipids with positive charge or even polymers with mucoadhesive
Pharmaceutics 2019, 11, 460 14 of 29
properties in the liposomes. Experimentally, the liposomes with cationic nature displayed improved
capacity to deliver their content in the ocular tissues in comparison to negative or neutral charged
liposomes. This phenomenon is a consequence of the interaction with the negative charge of the
corneal tissues [139,140].
Liposomes with anionic and cationic shielding were arranged with an acyclovir content.
To accomplish so dicetylphosphate and stearylamine were charged to play, correspondingly, the
role of anionic and cationic inducers. After topical application into the eyes of the rabbits, the
concentrations of acyclovir were assessed after 2.5 h exhibited the cationic liposomes in a superior
concentration in the cornea tissues than anionic liposomes or acyclovir alone. The cationic liposomes
were even more easily absorbed throughout the cornea tissues. Overall, these results point to the
negative-charge nature of the surface of the cornea and to the best binding capacity of the positively
charged formulations that interact electrostatically with the ocular structure being more easily absorbed
as well as kept [141].
Another study demonstrated that the delivery of Coenzyme Q10 (CoQ10) in liposomes coated
using trimethyl chitosan mucoadhesion strategies increased the residence time in the tissues of the
precorneal segment of the eye of rabbit 4.8-fold [142]. Regarding other strategies for delaying the
clearance of liposomes from eye tissues, as in the posterior portion of the eye, the hindering of enzymatic
reactions or purely chemical degradation of unstable molecules as nucleotides of peptides is a desired
aspect. As an example, it can be referred that fluconazole had its half-life intensified from 3.08 h to
23.4 h when administered as a liposome formulation in the vitreal portion of the eye [143]. In the
same line of illustrative act, a study with tacrolimus formulated in liposomes to treat the condition of
uveoretinitis, applied the product only once through an intravitreous procedure further observing that
a concentration of 50 ng/mL was kept for a period of 14 days. The formulation was also revealed to
decrease the intrinsic toxicity of the drug in the internal retinal cells and blocked the uveoretinitis more
efficiently in contrast to the drug alone [144].
Currently, a vast array of pharmaceutical formulations using liposome technology are in survey
with a restricted number being submitted to pre-clinical and clinical trials and an even scarcer number
available commercially [145]. The products Tears again® and Visudyne® are clear illustrations of
these formulations already available on the market to treat ophthalmic diseases. The first product
consists in a spray made of liposomes of phospholipid nature for the conditions of dryness of the
eyes which has successfully demonstrated clinical noteworthy returns in comparison to isotonic saline
solutions and gels with triglycerides [146,147]. The second product is applied in the condition of
macular degeneration age-related as a therapeutic to revascularize the subfoveal choroidal tissues
using the liposomal formulated verteporfin, a photosensitizer employed in photodynamic therapy.
Other illnesses on which it may be applied are myopia or histoplasmosis of the eye [148,149].
2.3.1. Nanomicelles
Nanomicelles possess exterior hydrophilic polar heads and an interior hydrophobic fatty acyl
chain which makes them capable of delivering poorly water-soluble drugs and of protecting molecules
such as proteins or peptides. Such structures are amphiphilic and can possess in their nature an
intrinsic capacity to be polymers or surfactants [150,151]. Fresh review studies performed by Cholkar et
al. demonstrated the critical boundaries in the application of these systems for attaining the purpose of
delivering drugs for the treatment of ocular tissues. The main advantages of such type of formulation
are related with the ability to be easily prepared, the final small size they yield, and the tremendous
capacity to encapsulate high quantities of drugs. As a direct consequence, the formulations carrying
such morphology allow increased bioavailability of the drugs to be administered with further acquired
improved clinical results [152,153]. Several clinical studies carried out with different drugs used
the formulation format of nanomicelles. A study conducted by Civiale et al. settled nanomicelles
fulfilled with dexamethasone using an objective copolymer of poly hydroxyethyl aspartamide (PHEAC)
and its respective pegylated molecule to vector the formulation to the anterior portion of the eye
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globe of rabbits. To assess the concentrations of the drug, the aqueous humor was extracted and
analyzed revealing that dexamethasone encapsulated in nanomicelles of PHEAC had increased values
for bioavailability compared to usual suspensions of this drug with an overall quantity value 40%
higher than the control suspension formulation. The results pointed to the worthwhile opportunity
of applying these formulations of nanomicelles to deliver small molecules to the ocular tissue by
topical application [154]. The nanomicellar systems were also used in gene therapy for the ocular
globe. Another study, this time carried out by Liaw and collaborators, aimed to delivery certain genes
into the corneal tissues using topical administration. A copolymeric lattice based on poly(ethylene
oxide)-poly(propylene oxide)-poly(ethylene oxide) was reported to be a carrier for the delivery of
selected genes incorporated into plasmids containing the DNA of interest fused with a reporter gene,
in this case the LacZ transfected into mouse and rabbit eye tissues. After achieving the results, it was
clear that these systems were a considerable possibility to transfer genetic information. Further
researches with other genomic information—tissue-specific promoters—were conducted with the
promoters keratocan and keratin 12. The overall expression of the genes of interest was assessed
using the activity of another reporter gene which is translated into the functional β-Gal enzyme which
converts a reagent into a color-identifiable molecule. The identifiable color was visualized after six days
of continuous administration, three times a day, of pK12-Lac Z-PM, an eye drop formulation, applied in
the corneal tissues of mice and rabbits. Also, the most feasible mechanism responsible for the process
of transfection was the endocytic pathway combined with the relative size of the obtained particles
through paracellular transference [155]. One of the most recent ocular products using nanomicelles
is CEQUA™. This product is a cyclosporine ophthalmic solution at 0.09% is a calcineurin inhibitor
immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca
(dry eye) [156].
Other strategies being put in use are concerned with the use of nanomicellar systems to deliver the
desired therapeutics to the posterior portion of the eye, a fact recently achieved. Aiming the cumulative
validation of the previous obtained results other studies were performed but, instead, with voclosporin
encapsulated in nanomicelles, in rabbit animal models. The outcomes demonstrated a good capacity
to penetrate eye barriers and a parallel outstanding profile of delivery to the posterior region of the
eye [150].
A research group governed by Ideta tried to distribute a fluorescent-conjugated compound,
poly-l-lysine labeled with fluorescein isothiocyanate (FITC-P(Lys)) to the posterior portion of the
ocular globe of the animal model trying to stimulate the angiogenesis. For such a purpose they
used an intravenous injection of the drug formulation. The results showed that the administration
of FITC-P(Lys) without previously formulating it resulted in the death of the animals 1-h post
administration. On the other hand, the administration of FITC-P(Lys) previously formulated in a
micelle network made of polyethylene glycol and poly-α, β-aspartic acid in a repetitive mesh lead to no
animal death. Such outcomes reveal the presence of a non-existent quantity of drug in the formulated
design. Pharmacokinetic assay revealed a peak of micellar concentration (maximum concentration),
4 h after a unique administration, in the portion of retina and choroid membranes. Additionally,
the drug was also sensed 7 days after the administration. The perceptible longer times of circulation
of the formulation are due mainly to the ratio between polymer and drug. The authors also stated
that the extended times of circulation of micelles may increase the permeation and retention at the
places where the angiogenic effects were required [157]. The great observed advantage is related to the
selective accumulation of the formulation in ill tissues in comparison to normal tissues.
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The presently-used strategies are devoted to deliver active pharmaceutical ingredients through
a non-invasive route to both anterior and posterior portions of the eye. Following this principle,
the actual trends in nanomicelles’ development are achieving more attention from experts due to the
topical application strategy avoiding invasiveness. Using personalized skills such as the very small size
attached to the presence of a halo of hydrophilicity nanomicelles may be held in the systemic circulation
for extended periods, with an increased accumulation in the desired ocular portion, derived from the
electrostatic interactions (negative–positive charged surfaces) and from the increased permeability of
the damaged portions. Consequently, it allows the drug to be permeated and accumulated specifically
in the ill regions. Yet, the design and engineering of the formulation regarding the choice of the
polymers and surfactants employed is also a determinant step in the accomplishment of a final
optimized product [158,159].
2.3.2. Nanoparticles
The nanoparticulate systems are chemically characterized as colloidal transporters ranging from
10 nm to 1000 nm. In order to be applied in the ophthalmic tissues these arrangements required specific
compositions to assure safety and efficacy: Proteins and lipids were employed as well as polymers from
synthetic or natural sources, amongst them chitosan, albumin, sodium alginate, polylactic acid (PLA),
poly(lactide-co-glycolide) (PLGA) or polycaprolactone. Also, the nanoparticle-encapsulating drugs
may be divided in two principal devices: Nanocapsules and nanospheres. The first have the drug
encapsulated in the interior of the polymeric lattice formed. The second have the drug homogeneously
dispersed along the polymeric lattice. In recent years, nanoparticulated engineered forms apprehended
the interest of several research groups to develop delivery systems intended to specifically carry drugs
to anterior and posterior ocular tissues [160,161].
The small size of nanoparticles is a very good feature for their promising characteristics for
diminished irritation in the corneal tissue and capacity to sustain the delivery of the drug with further
avoidance of multiple administrations, which are related to therapeutic compliance. Nevertheless,
these hydrophilic formulations may also be subjected to quick elimination from the precorneal
compartment. On behalf of this, nanoparticles possessing mucoadhesive characteristics were prepared
aiming to be topically administered, with consequent improved time of residence in the precorneal
compartment. To enhance the time of permanence of the nanoparticles in the previous mentioned
compartment some compounds are currently used as chitosan, hyaluronic acid, or polyethylene glycol
(PEG) [162]. Among these, coating with chitosan is the preferred method to achieve the purpose
referred to. As this molecule has a positive charge it is attracted by the negative surface of the cornea
further improving residence time and diminishing clearance of the formulation [6,7,163,164]. In a study
conducted with natamycin-encapsulated nanoparticles structurally made up of a mixture of chitosan
and lecithin, it was proved that those particles were demonstrated high bioavailability in a rabbit
ocular globe with both lower dosing and doses in comparison to the marketed suspensions reported
for the same effect [165]. Another study carried out by Musumeci et al. stated that nanoparticles
constituted with a mixture of PLGA-PEG and being further fulfilled with melatonin were successful in
lowering the intraocular pressure in rabbits, comparative to nanoparticles engineered only with PLGA
and further fulfilled with melatonin or even with other aqueous solutions. A proposal to explain the
results is that nanoparticles manufactured with PLGA-PEG achieved a reduced zeta potential relative
to PLGA-nanoparticles. Due to this, the first ones were successfully able to interact with the eye surface
yielding a longer hypotensive effect [166].
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As an alternative to the process of delivering of drugs to the posterior section of the eye,
the nanoparticulate system aims to sustain the delivery for long periods. The main features which
influence the penetration of nanoparticles into this portion are the size and the properties of the
surface [167,168]. A periocular injection into the animal model ocular tissues, probably due to specific
removal by such tissues as eye conjunctive and episcleral. Among the results it was verified that
particles with a size ranging between 200 nm and 2000 nm were capable of being taken efficiently
and kept by the tissues where they have been administered for a period up to two months; also,
the nanoparticles with a small size, chiefly as a consequence of their capacity to rapidly release the
content and be cleared, are not capable of sustaining the drug levels at the retina [169]. After the
application of the intravitreal injection the nanoparticulated systems travel via several layers of the
retina. The capacity of the nanoparticles to pass from the vitreous humor to various retinal tissues is
mainly due to the properties of the nanoparticles’ surface.
With the previous mentioned factors, it can be elicited that the actual and future products proposed
for extended delivery of drugs to the posterior portion of the eye, which will surpass the transscleral
barrier, must have such features as gradual drug release and a parallel diminished clearance by the
organism blood and lymph vessels to be potential candidates for patented formulations [170].
2.3.3. Nanosuspensions
These formulations are obtained using surfactants or polymers to stabilize the particles constituted
by drugs, but on a submicron range which, by turn, form colloidal dispersions. This system is quite
appropriate to encapsulate hydrophobic drugs. Applying such formulation to the ocular route of
delivery yields optimal outcomes when compared to other usual ophthalmic products—diminished
irritation, better profile as eye drops, augmented half-life time in the precorneal tissue, sterilization of the
product, and improved capacity to solubilize hydrophobic drugs in the lacrimal fluid [171,172]. Some of
these effects were also tested in the improved solubilization of glucocorticoids using nanosuspensions
for ocular purposes. When referring to pathological conditions in which a variable degree of
inflammation is present, disturbing the anterior portion of the ocular tissues, the glucocorticoids as
dexamethasone, hydrocortisone, and prednisone are the preferential drugs to treat such illnesses.
Nowadays, a therapeutic scheme uses recurrent high doses of the previous pharmacological agents
with further initiation of cataract, optic nerve damage, and even glaucoma as undesirable side effects.
On behalf of this, the glucocorticoids were so formulated with the model of nanosuspensions to
increase the ocular bioavailability of the mentioned drugs [173,174]. Studies conducted by Kassem
et al. compared two variables: The ocular bioavailability of glucocorticoid molecules as formulated
in microcrystalline suspensions, nanosuspensions, and solutions. The intraocular pressure on the
rabbit eye was assessed, for a period up to 12 h, after instillation of the given formulations in
the previous referred structure. The results showed that all suspensions presented higher area
under the curve (AUC) values in comparison to solutions of drugs with the drugs formulated in
nanosuspensions determined to have extensive absorption and increased therapeutic effect in relation
to drug solutions [171,175]. Other research carried out by Ali and collaborators related the variable
bioavailability of hydrocortisone nanosuspensions formulated using precipitation methodologies with
the same parameter on hydrocortisone solutions settled with milling apparatus. The research group
used as a rabbit as a model and the formulations were applied as a topical instillation. Here, again,
nanosuspensions revealed better results with significant increased bioavailability in comparison to
solutions [176]. Using these studies, it can be logically inferred that nanosuspensions can be outlined as
efficient formulations to optically deliver poor soluble drugs and can even be merged with hydrogels
or ocular implants.
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2.4. Microneedles Technology
The technology based on the development and production of microneedles is based on a preference
for minimal invasiveness. These microneedles possess the capacity to deliver a vast array of drugs
to ocular tissues located in the posterior portion of the eye. Along with this, some aspects of the
therapeutics may be overcome as the case of the intravitreal injections which possess many frightful
consequences such as cataracts, endophthalmitis, hemorrhage, and retinal detachment, allowing to
surpass the previous implications. The therapeutic outcomes may also be increased in such diseases
as diabetic retinopathy and age-related macular degeneration [149–152]. Also, this strategy has the
capacity to exceed the blood–retinal barrier and deliver higher quantities of drug to the inner portions
of the eye preventing also the distribution to unwanted tissues. The formulation of microneedles is
also customized to create structures which will only penetrate hundreds of micrometers in the sclera
of the eye to circumvent possible damages to deeper assemblies in the eye. With the employment of
microneedles, it is possible to specifically place the drug or drug systems into the eye sclera or other
intermediate space, namely the suprachoroidal space [153–155]. A study using eyes of human corpses
demonstrated that microneedles coated with drugs, namely sulforhodamine, verified rapid dissolution
of the therapeutic molecule within the sclera [156]. Another study proved that microneedles wrapped
with drugs formulated as nanoparticles or microparticles were able to deliver to sclera an infusion of,
approximately, 10 to 35 µL of drug solution, confirming the enormous potential of microneedles to
be employed in ocular delivery of drugs with few invasiveness [158]. Another study carried out by
Patel et al. was able to demonstrate that microneedles optimized for suprachoroidal delivery were safe
enough to be applied obtaining also suitable patterns of controlled drug release [159].
3. Ocular Gene Delivery
In the last three decades until now gene therapy has achieved a tremendous increase in acceptance
from academic milieu and from clinical centers around the world. This technique hires viral vectors
which carry material with genetic nature to be specifically delivered into the desired cells. Despite this,
the overall process is not perfect and systemic toxicity effects arose. Further developments in this field
lead to new avirulent viral strategies with improved capacity to target a tissue (Table 4). The herpes
simplex virus-1 ribonucleotide reductase-deficient (RR(-)HSV1) is considered one of the best systems
to be pragmatic in the vectorization process of genomic material [177]; inclusively, the United States
have a declared patent recognizing the attempt to incorporate a bovine gene for bFGF in the RR(-)HSV1
with posterior analysis in animals revealing fruitful incorporation [178]. This and other backgrounds
captured the attention of several researchers for the possibility to use these concepts and deliver other
molecules with significant biological roles as cytokines, neurotrophins, or growth factors to be applied
in other body tissues [179–181].
In another study, the segment of genomic DNA which encodes the information for pigment
epithelium-derived factor (PEDF), a proved molecule in the process of protection contrary to
neovascularization of choroid membrane, was delivered using a recombinant adeno-associated
viral vector (rAAV) to increase the expression of the related gene, with the obvious phenotypic
consequences. The researchers used the mouse animal model and the results showed a successful
delivery of the information of interest regarded as diminished sizes of the choroid neovascularization
lacerations, induced by laser application, observed after injection of the formulation. To properly
achieve results the delivered material must contain tissue-specific promoters, several enhancers and
other factors for efficient transcription and translation of the gene(s) of interest [182].
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Table 4. Ocular delivery systems for gene therapy.
Patented System Clinical Application Year Reference
Methodology for gene detection with a parallel development of an animal
model to assess the effectiveness of the developed compound against the
target genes
Genetic pathologies implicated in age-related Macular
Degeneration (AMD) and destruction of Retinal
Pigment Epithelia
2009 [183]
Lentiviral vectors aiming the transduction of inactive and mitotically
active cells Proliferative ocular disease 2006 [184]
Delivery system for genes as recombinant vectors Retinal illnesses associated with lysosomal disordersof storage 2003 [185]
Adeno-associated recombinant viral vector for delivery of
antiangiogenic factors
Handling of illnesses related with the posterior segment of
the eye 2002 [186]
Diagnostic test to identify aberrant pitx3 polypeptides Dysgenesis of the mesenchymal anterior portionor cataracts 2001 [187]
Inhibitor of RTP801 gene Microvascular illnesses of the eye 2011 [188]
GFR alpha3 agonist Retinal disorders 2008 [189]
Modulation of gene expression through narrow band multichromatic
electromagnetic radiation Ocular disorders 2010 [190]
Formulation with 15-lipoxygenase-1 gene to substitute epithelium from the
surface of the eye Dry eye in postmenopausal women 2006 [191]
Method for identification of freac3 gene Susceptibility of humans to glaucoma and anteriorsegment dysgenesis 2003 [192]
Hyaluronic acid dihydrazide-derivated or conjugated with nucleic acids Dry eye syndrome 2003 [193]
Viral vector system for delivery system of glial cell-derived neurotrophic factor Ocular illnesses 2003 [194]
Novel electroporation methodology to carry RNA molecules to specific spots
in the eye Ocular gene-controlled expression 2005 [195]
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Another technique relies on the use of short-interfering RNA (siRNA) which can modulate the
expression of a given gene according to the correspondence between the sequence of the siRNA
molecule and the endogenous mRNA to be silenced. The exogenous molecule is easily delivered
through the cell membrane and, in virtue of such, a fresh patent declared the formulation of a cationic
polymer which was synthesized and further complexed with the molecule of siRNA. Using the ratio
between the number of genomic molecules and cations present, the overall electrical charge of the
formulation is possible to be modulated—positive, negative or neutral charge. In a study carried out the
siRNA molecules were pointed as inhibitors for mRNA responsible for angiogenic processes, related
with the receptors for VEGF1, VEGF2, and VEGF3. The results were clear enough to demonstrate
the capacity of the administered formulation to diminish the expression of the gene of interest by
20% [196].
Chalberg et al. filled out a patent process related with the delivery of nucleic acids to the
ocular globe. The methodology is based on the capacity of a high-intensity current to permeate the
cell membrane generating a mechanical stress in the cell apparatus [197]. After this, the genomic
information encoded by a nucleic acid molecule enters the cell and is translated into therapeutic protein
molecules. This type of procedure may be used for treatment of such diseases as glaucoma or age-related
macular degeneration. Further, the reported gene was used to spot the transfected conjunctival tissues
but without using the previously-mentioned patented technique and then compared with the results
of the used method. The analysis of the outcomes demonstrated a bioluminescence 2-fold higher
in the tissues transfected with the patented methodology in comparison to the procedure without
this technique, revealing a successful process of transfection in the first case [198]. Currently, quite a
range of researchers worldwide are involved in the development of new viral vectors to avoid toxic
effects after the administration via ocular route and to circumvent other reactions, such as tumor
development and multiple organ failure. Although the experiences in animal models have been a
success, a much more careful planning and regulation of these complex, dangerous, but, in parallel,
extremely advantageous systems is required, to be applied in human trials to further assess possible
extrapolations targeting future therapeutics for until now uncurable diseases [199,200].
4. Conclusions
For quite a few decades, the mechanism of specific drug delivery to ocular milieu was indeed a
challenge [201,202]. The common pharmaceutical formulations applied to this purpose, drugs applied
as eye drops, suffered downsides which, by turn, required the implementation of distinct carriers
aimed in ocular administration route. Aiming to surpass such limitations, deep investments have
been made in the field of ocular research to produce safe systems allowing higher rates of therapeutic
efficacy and better compliance by patients. Nowadays, scientists are devoting their efforts to achieve
advances on in vivo models to further apply the upcoming innovations in clinicals trials. Besides,
the dawn of the nanotechnological era with forthcoming production methods and arising technologies
with supplementary possible applications on ocular delivery systems developed a growing interest in
the scientific community working on this field [203–205]. New methodologies for drug encapsulation
are being carried out to engineer these nanosystems which will then be administered according to
invasive, non-invasive or slightly invasive techniques. In parallel with these advances, the fresh
systems—such as dendrimers, liposomes, nanomicelles, nanostructured lipid carriers (NLC), and solid
lipid nanoparticles (SLN)—are being thoroughly studied but with few commercially-available options.
The preclinical safety of lipid nanoparticles (SLN, NLC) has already been reported for a range of
applications including its use as ocular drug delivery systems [206]. The development of these
nanotechnological approaches brings new possibilities to therapeutics by reducing the side effects
frequently induced by intrinsic toxicity of the drug molecules on the organism of the patient which can
inclusively lead to loss of vision. Additionally, the innovative technologies possess other advantages to
such therapeutic outcomes as the capacity to be more specific to certain tissues using specific superficial
molecules supporting the reduction of the administered dose frequency and even the pharmacokinetic
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profile of the medicine. Nevertheless, the necessity for vectorized systems to the ocular tissue is still
a requirement, especially for tissues localized in the posterior portion of the eye avoiding also an
invasive procedure. Thus, in the near future, the delivery systems to be commercialized will certainly
exceed current invasive techniques.
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